en · de · es · pt
tesamorelin-notes.peptides3626.com › Info › �£€测方法、储存与处理 — Quick Reference

�£€测方法、储存与处理 — Quick Reference

By Editorial Desk · published 2025-07-31 · last reviewed 2025-09-02 · Info

GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-09-02. Anything still debated is marked as such rather than presented as settled.

检测方法、储存与处理

纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质,给出纯度百分比与保留时间;电喷雾或基质辅助激光解吸电离质谱提供分子量,用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析,不同方法之间需要做交叉校验。

冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存,可维持较长时间的稳定。复溶后稳定性明显下降,溶液中的肽链易发生水解、氧化与聚集,通常需冷藏并在短期内用完。反复冻融会加速聚集与降解,建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率,需要按具体实验条件验证。

研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平,各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果,使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证,这些信息决定结果能否被外部重复。

Biological Role and Origin

The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.

Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.

The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.

Tesamorelin at a glance

性质取值备注
外观白色至类白色冻干粉常见形态
溶解性易溶于水与水性缓冲液多肽类通性
典型储存温度-20°C 或更低干燥避光
常用纯度方法反相高效液相色谱214 nm 紫外检测
常用分子量确认质谱电喷雾或激光解吸

特沙莫瑞林分析与储存要点

稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定,复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集,这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。

质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成,纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同,前者常缺少完整药典验证。不同批次间杂质谱是否影响活性,仍是一个需要具体数据回答的问题。

Related pages on this site

Background and Clinical Development

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Supporting material

=== Pharmacodynamics === Esketamine is approximately twice as potent an anesthetic as racemic ketamine. The possibility that arketamine may be more effective than esketamine has been suggested by some researchers. Esketamine inhibits dopamine transporters eight times more than arketamine. This increases dopamine activity in the brain. At doses causing the same intensity of effects, esketamine is generally considered to be more pleasant by patients. Patients also generally recover mental function more quickly after being treated with pure esketamine, which may be a result of the fact that it is cleared from their system more quickly. However, this observation contrasts with findings that arketamine exhibits antidepressant effects without causing psychotomimetic side effects. Unlike arketamine, esketamine does not bind significantly to sigma receptors. Esketamine increases glucose metabolism in the frontal cortex, while arketamine decreases glucose metabolism in the brain. This difference may be responsible for the fact that esketamine generally has a more dissociative or hallucinogenic effect while arketamine is reportedly more relaxing. However, another study found no difference between racemic ketamine and esketamine on the patient's level of vigilance. Interpretation of this finding is complicated by the fact that racemic ketamine is 50% esketamine.

=== Removal rate === A drug's removal rate will be determined by the proportion of the drug that is removed from circulation by each organ once the drug has been delivered to the organ by the circulating blood supply. This new concept builds on earlier ideas and it depends on a number of distinct factors:

== External links == Acidity–Basicity Data in Nonaqueous Solvents Extensive bibliography of pKa values in DMSO, acetonitrile, THF, heptane, 1,2-dichloroethane, and in the gas phase Curtipot All-in-one freeware for pH and acid–base equilibrium calculations and for simulation and analysis of potentiometric titration curves with spreadsheets SPARC Physical/Chemical property calculator Includes a database with aqueous, non-aqueous, and gaseous phase pKa values than can be searched using SMILES or CAS registry numbers Aqueous-Equilibrium Constants pKa values for various acid and bases. Includes a table of some solubility products Free guide to pKa and log p interpretation and measurement Archived 2016-08-10 at the Wayback Machine Explanations of the relevance of these properties to pharmacology Free online prediction tool (Marvin) pKa, log p, log d etc. From ChemAxon Chemicalize.org:List of predicted structure based properties pKa Chart [1] by David A. Evans

Sources: en.wikipedia.org

Supporting material

The subscripts simply refer to the respective nuclides, i.e. NA is the number of nuclides of type A; NA0 is the initial number of nuclides of type A; λA is the decay constant for A – and similarly for nuclide B. Solving this equation for NB gives:

(CH2CH2)O + HCN → HOCH2CH2CN →−H2O CH2=CH−CN Addition of hydrocyanic acid to ethylene oxide is carried out in the presence of a catalyst (sodium hydroxide and diethylamine), and dehydration of cyanohydrin occurs in the gas phase upon the catalytic action of aluminium oxide.

Susie Orbach (born 6 November 1946), psychotherapist, psychoanalyst, writer and social critic; daughter of Maurice Orbach, author of Fat is a Feminist Issue, married to author Jeanette Winterson. She is honoured in BBC'S 100 Women in 2013 and 2014. She was the therapist to Diana, Princess of Wales during the 1990s. Yotam Ottolenghi (born 14 December 1968), Israeli-British celebrity chef; journalist for The Guardian and Haaretz; author of several cookery books, including Ottolenghi: The Cookbook (2008), Plenty (2010), Jerusalem (2012). Moved to Europe after his service in Military Intelligence Directorate (Israel); in 2014, London Evening Standard remarked that Ottolenghi had "radically rewritten the way Londoners cook and eat"; in 2017 was guest judge on Masterchef Australia. Ilan Pappé, pro-Palestinian dissident Israeli-British scholar, writer and author of Ashkenazi origin, focusing on the history of Palestinian Nakba, intifada, insurgency, land ownership and rights and radical Anti-Zionism. Joseph Pardo (c. 1624 – 1677), hazzan and writer David Patrikarakos; journalist and war correspondent, author of War in 140 Characters: How Social Media Is Reshaping Conflict in the Twenty-First Century; wrote Nuclear Iran: Birth of An Atomic State which was named as a New York Times Editor's Choice and nominated for Total Politics Book Awards. Ruthie Pearlman, Orthodox Jewish Crime Writer and writer of Young Adult Fiction.

== Financial information == From the founding of the company in 1976 to 1988, the revenue of KCI grew to US$153.2 million. The growth in revenue allowed KCI to go public and trade on the New York Stock Exchange (NYSE) in 1988. KCI stock was traded on the NYSE until 1997, when the company went private. In February 2004, KCI became a publicly listed company for the second time and was listed on the NYSE under the ticker symbol KCI. By the late 2000s, the company's revenue was over $1 billion and reported an increase of 17 percent in 2007 to $1.61 billion. Revenue for 2008 was $1.88 billion, increasing to $1.99 billion in 2009 and in 2010 increased to $2.02 billion. On November 4, 2011, the company went private again at a price of $68.50 per share.

Sources: en.wikipedia.org

Frequently asked questions

为什么常用反相高效液相色谱做纯度测定?

多肽在反相柱上按疏水性差异分离,能有效区分主峰、缺失序列片段与氧化产物。配合紫外检测可获得可量化的纯度百分比,是肽类分析的常规手段。

冻干粉应如何保存?

一般建议密封、避光、干燥,并在 -20°C 或更低温度下存放。温度波动和湿气是主要风险,长期存放应避免反复开启容器。

复溶后可以保存多久?

没有统一答案,取决于缓冲液、浓度、pH 与储存温度。多数做法是冷藏并在数天至数周内用完,具体期限需要通过稳定性实验确认。

What distinguishes tesamorelin from natural GHRH?

It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.

Network